Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ: GMAB )

22.44 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,421
Open 22.44
Bid (Size) 22.41 (13)
Ask (Size) 22.44 (18)
Prev. Close 22.44
Today's Range 22.44 - 22.44
52wk Range 18.64 - 31.88
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
In a market where value is scarce, NASDAQ:GMAB offers a refreshing opportunity with its solid fundamentals.
Take a closer look at GENMAB A/S -SP ADR , a remarkable value stock. NASDAQ:GMAB excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill

Performance

YTD
+6.86%
+6.86%
1 Month
+2.94%
+2.94%
3 Month
+9.62%
+9.62%
6 Month
-16.95%
-16.95%
1 Year
-22.49%
-22.49%

More News

Read More
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
Via Chartmill
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
Via Chartmill
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
Via Chartmill
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Via Chartmill
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.
Via Chartmill
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
NASDAQ:GMAB appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:GMAB.
Via Chartmill
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
From Genmab A/S
Via Business Wire
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
A Closer Look at 10 Analyst Recommendations For Genmab
Via Benzinga
Preview: Genmab's Earnings
Via Benzinga
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Why NASDAQ:GMAB Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
For those who appreciate value investing, NASDAQ:GMAB is a compelling option with its solid fundamentals.
Via Chartmill
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
Via Chartmill
12 Analysts Have This To Say About Genmab
Via Benzinga
NASDAQ:GMAB qualifies as a high growth stock and is consolidating.
Via Chartmill
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
From Genmab A/S
Via Business Wire
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
Via Chartmill
NASDAQ:GMAB is an undervalued gem with solid fundamentals.
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.